Offering routine genetic testing for Motor Neurone Disease (MND) could improve knowledge of disease classification and impact clinical care, new research has concluded.
Routine testing may be appropriate for all MND patients – whether or not they have a family history of the disease – and could impact disease sub-classification and clinical care, the findings of the Sheffield Institute for Translational Neuroscience (SITraN) study revealed.
Currently only patients with a family history of MND, dementia, or who experience disease onset at a young age are routinely offered genetic screenings in the UK.
With the development of new therapies targeting specific genetic forms of the disease, researchers on the study – which was funded by the are recommending that all MND patients are offered a screening.
“Our study suggests that all patients with MND should, with careful counselling, be offered genetic testing,” says Professor Dame Pamela Shaw, Director of SITraN and the NIHR Sheffield Biomedical Research Centre.
“We hope that by screening all MND patients for gene mutations that are a known factor in MND, we can further our knowledge on subclassification of the disease, but also ensure that patients have access to clinical trials that are relevant for them personally.”
MND – also known as amyotrophic lateral sclerosis (ALS) – is an adult-onset neurodegenerative disease characterised by progressive injury and cell death of upper and lower motor neurons.
This leads to progressive failure of the neuromuscular system with death, usually from respiratory failure, within 2–5 years of symptoms in most cases.
Currently, there is no cure for MND – which affects 5,000 people in the UK and 450,000 people worldwide – and no effective treatments to halt or reverse the progression of this devastating disease.
Among the 100 patients who took part in the study, researchers found higher than expected genetic changes in the group of patients.
“Our study found that 42 per cent of patients involved in the screening showed variants in known MND-linked genes,” says Professor Janine Kirby, Professor of Neurogenetics at the University of Sheffield.
“This doesn’t mean that 42 per cent of MND cases are familial – but shows that some familial and sporadic cases can share the same genetic cause of disease.
“We found that 21 per cent of patients had a clinically reportable genetic alteration that has been proven to increase the likelihood of developing MND.
“Of these, 93 per cent had no family history of MND and 15 per cent met the inclusion criteria for a current MND gene therapy clinical trial.
“As future studies expand the number of verified genetic causes of MND, we will continue to see if they are also found in cases without a family history.
“This is increasingly important in light of the new personalised medicine treatments in development for MND that target a specific gene mutation to ensure that patients have access to potential treatments that could be beneficial to them.”
Dr Brian Dickie, director of research development at the MND Association, adds: “MND is a complex disease involving a complex mix of genetic and environmental factors.
“This latest research sheds more light on the genetic component and will hopefully lead to greater availability of genetic testing to aid earlier diagnosis and more tailored treatments in the future.
”This will provide an even clearer picture of the UK MND genetic landscape.’’
£1m dedicated to MND research through 7 in 7 Challenge
A £1million fund has been created to lead new research into potential treatments for Motor Neurone Disease (MND) through the efforts of an iconic challenge by Kevin Sinfeld.
Kevin, director of rugby at Leeds Rhinos, raised over £2million through his 7 in 7 Challenge, inspired by his former team-mate and close friend Rob Burrow.
Rhinos legend Rob was diagnosed with MND in December 2019, and Kevin completed seven marathons in as many days to help boost badly-needed research into the condition.
Now, with £500,000 of the money raised through the 7 in 7 Challenge ring fenced for research, that sum has been matched by medical research charity LifeArc.
The move has created a £1million joint fund established by the MND Association and LifeArc, which will support research projects focused on developing new therapies or repurposing drugs already approved for use for other conditions.
“This is fantastic news and an amazing contribution from LifeArc,” says Kevin.
“When we set out to complete the 7 in 7 Challenge we hoped to raise awareness and funds to support the MND community but it is so wonderful to see the inspiration it has given people and organisations, like LifeArc, so they too can support the need for more research.
“Our hope, like that of everyone affected by this brutal disease including Rob, is that this money will make a real difference and help find the breakthrough we all desperately want.”
Researchers are now able to apply for a share of the funding, with the criteria that they will be expected to conclude their project within three years and be target driving with set milestones and a credible delivery plan – including a clear route to reach MND patients.
Dr Brian Dickie, director of research development at the MND Association says: “We are so grateful to LifeArc for this generous contribution and are looking forward to working with them to identify projects which have a real chance of making a difference to our community in the coming years.”
Melanie Lee, LifeArc’s chief executive, emphasised that the focus of the new funding is on boosting research around potential treatment options based on the latest understanding of the disease.
“The ambition around stimulating the search for new treatments fits with LifeArc’s approach over the last 25 years to translate early science into health care treatments or diagnostics that can transform patients’ lives,” she says.
“Our partnership with the MND Association is the latest in a series of strategic partnerships that maximise LifeArc’s expertise in translating strong discoveries from the lab into benefitting patients with conditions with few or no effective treatment options.”
What causes a stroke?
Over 100,000 people in the UK suffer a stroke each year, with there currently being around 1.2 million survivors living in the country.
Many people note that despite how common strokes are they remain unaware of what the actual causes of a stroke are.
Depending on which of the two types develops, causes and outcomes can differ.
What both have in common is they restrict blood flow to the brain. This leads to a reduction in the brain’s oxygen levels, which can cause tissue damage.
Here, NR Times breaks down why a stroke may occur and what risk factors there are behind each different type.
What are the different types of stroke?
There are two main types of strokes: ischaemic and hemorrhagic.
Ischemic strokes make up nearly 90 percent of all cases and they materialise when an artery which provides blood and oxygen to the brain becomes blocked.
A hemorrhagic stroke is much less common, but happens when an artery leading to the brain bursts and starts to leak blood around or in the brain.
Causes of an ischaemic stroke
The brain is only able to function properly when its arteries supply it with oxygen-rich blood, meaning any blockages can cause lasting damage.
With a lack of blood flow, the brain is unable to make enough energy to work. If this consists for more than a few minutes, brain cells will begin to die.
This is exactly what happens in an ischaemic stroke, but there are a range of reasons as to why these blockages develop.
One of the main causes is when the arteries around the head narrow, which makes it harder for the blood to pass through.
This can also lead to something called atherosclerosis, which is where substances in the blood (such as fat or cholesterol) stick to the sides of the arteries.
Blood can build up on these deposits, causing a further increase in pressure and a reduction to the brain’s oxygen supply.
There are a number of reasons for these blockages, with the most common ones being around a person’s lifestyle.
For example, smoking can increase the risk of a stroke by up to 50 percent.
This is because nicotine not only narrows the arteries, but it also makes the heart beat faster, causing an increase in blood pressure.
Excessive alcohol intake, obesity and high cholesterol levels are also all listed as major risk factors when it comes to ischaemic strokes.
Problems with the arteries around the heart can also lead to an ischaemic stroke.
Irregular heartbeats, heart attacks and other irregularities around this area can again limit the blood’s oxygen levels.
Causes of a hemorrhagic stroke
Hemorrhagic strokes are most common in people ages 45 to 70, but they affect a lot more younger people than an ischaemic stroke.
These are caused after the arteries around the brain burst and cause bleeding.
Depending on where the artery is can affect the outcome of the hemorrhagic stroke.
If the bleeding occurs within the brain, blood shooting out at high pressure can kill some cells.
Bleeding on the surface increases the pressure in the protective layer between the brain and the skull, potentially causing more cell loss.
This bleeding is normally caused by chronically high blood pressure. In many cases, the increased pressure can cause the arteries to expand and weaken, meaning a split in them is more likely to take place.
A rarer cause of hemorrhagic stroke is where the blood vessels around the brain are connected abnormally, causing further stress on the brain. These are congenital (present at birth) but the reason for their occurrence is currently unknown.
Again, the best way to reduce the risk of an hemorrhagic stroke is to make healthy lifestyle choices.
NHS pilots video service for epilepsy diagnoses
A new clinical video service which supports epilepsy diagnoses and management in the era of coronavirus and beyond has been launched in the UK.
vCreate Neuro allows registered patients and carers to share smartphone-recorded videos of potential seizures or unknown movements with their clinical team via a secure, NHS-trusted system.
The data and footage act as a visual aid to assist clinical teams with rapid precision diagnostics, creating a digitised clinical pathway that minimises the need for face-to-face clinic appointments and invasive tests.
The system is currently being piloted across Scotland and, following its initial success, across England including Great Ormond Street Hospital, Evelina London and Sheffield Children’s Hospital.
The system is available to families who are concerned that they, their child or loved one may be experiencing seizures or unexplained episodes including epilepsy.
Since May 2020, more than 2,000 families have shared over 5,000 videos with their clinical teams across the platform.
Dean MacLeod was referred to the service when her seven-year-old daughter, Olivia, began having unknown movements in May 2020.
Dean uploaded videos of Olivia during these episodes as Olivia’s seizures grew more frequent.
The videos were reviewed by Paediatric Neurology professionals at the Royal Hospital for Children, Glasgow, and, supported with telephone appointments, Olivia was diagnosed with a form of epilepsy and quickly started on treatment.
Speaking about her experience, Dean said: “I’ve found vCreate to be invaluable in Olivia’s journey since she started having seizures last summer.
“We live in a remote location on the Isle of Lewis, Scotland, and we have a very limited paediatric service on the Island. The service has made it easy to access the specialist clinical knowledge needed by sending recordings of various seizure events to the Paediatric Neurology team at Glasgow.
“Since the diagnosis, I have kept in regular contact with the clinical team through the platform, sending videos and typically receiving advice from a Consultant within 24 hours which is fantastic. Between the vCreate service and telephone discussions, our family have not needed to have face-to-face consultations which has been hugely beneficial during the pandemic.”
Professor. Sameer Zuberi, consultant paediatric neurologist at the Royal Hospital for Children, Glasgow, said: “vCreate Neuro has transformed how we use carer-recorded video in our service. We are diagnosing epilepsy more rapidly, preventing misdiagnosis and saving unnecessary investigations. Families feel in more control and better connected to the service.
During the Covid-19 pandemic, many people experiencing seizures and seizure-like episodes, including children, have been unable to see a clinician.
Create Neuro aims to help by empowering patients to use asynchronous video technology for self-management, reducing the need for physical appointments.
Founder Ben Moore said: “We’re passionate about family-forward care, and worked closely with clinical teams, patients and carers to develop the vCreate Neuro service.
“The system aims to improve patient care, reduce the number of clinic investigations – and resulting costs to the NHS – and digitise the patient pathway. We want families to be in control of their healthcare journey and have a direct link to their clinical team despite the pandemic restrictions.”
The vCreate platform has been independently assessed and approved by Information Governance teams in over 100 UK NHS Trusts.
Within the platform, a clinical database is available as a learning resource for clinicians to study seizure types, events, and other symptoms.
Brain injury4 weeks ago
‘I’m sorry for handling the steering wheel with buttered fingers’
Case management4 weeks ago
New case management business continues to grow
Brain injury4 weeks ago
Sleep problems ‘can be worse with mild TBI’
Neuropsychology3 weeks ago
Mental health issues ‘may stem from childhood cognitive problems’
Stroke2 weeks ago
Stroke Association launches long-term stroke/COVID study
Community rehab4 weeks ago
Finding a voice for Richie
Stroke2 weeks ago
Surviving stroke: the transition from hospital to home
Brain injury3 weeks ago
Impact of COVID-19 on brain to be investigated